Recent studies have shown that metastasis-associated protein-1 short form (MTA1s) -metastatic tumor antigen 1 short form sequesters estrogen receptor-alpha (ER-a) in the cytoplasm of breast cancer cells. Using a yeast twohybrid screening to clone MTA1s-interacting proteins, we identified casein kinase I-gamma 2 (CKI-c2, a ubiquitously expressed cytoplasmic kinase) as an MTA1s-binding protein. We show that MTA1s interacts with CKI-c2 both in vitro and in vivo and colocalizes in the cytoplasm. In addition, we found that CKI-c2 can phosphorylate MTA1s, but not ER, in an antiestrogendependent manner and that estrogen stimulates CKI-c2 activity that could be effectively blocked by a specific inhibitor of CKI. CKI-c2 could further potentiate the ER corepressive function of MTA1s. Kinase dead CK1-c2 could not repress estrogen-induced ER transactivation functions. Results from mutagenesis studies suggest that substitution of the serine residue at 321 to alanine, which is a possible CKI-c2 phopshorylation site in MTA1s, results in a significant reduction in the ability of MTA1s to repress ER transactivation. These findings identified MTA1s as a target of CKI-c2, and provided new evidence to suggest that CKI-c2 phosphorylates and modulates the functions of MTA1s, and that these extranuclear effects of estrogen might have important implications in regulating the functions of MTA1s in human mammary epithelial and cancer cells.
Introduction
Metastatic tumor antigen 1 (MTA1) was originally cloned by differential screening of the cDNA library from rat mammary adenocarcinoma metastatic cells (Toh et al. , 1994) . MTA1 expression has been shown to be upregulated in human tumor cell lines and tissues (Xue et al., 1998; Zhang et al., 1999; Mazumdar et al., 2001; Mahoney et al., 2002) . Recent studies suggested that MTA1 is a corepressor of ligand-induced transactivation function of estrogen receptor-a (ER-a) in breast cancer cells (Kumar et al., 2002) . MTA family members are increasingly being implicated in human cancers, and two naturally occurring variants of MTA1, ZG29p and MTA1s, have also been identified (Kumar, 2003; Kumar et al., 2003) . ZG29p is an N-terminal truncated form of MTA1 and is present in the zymogen granules of the pancreas (Kleene et al., 1999) , while MTA1s (for short version of MTA1), the C-terminal truncated form of MTA1s, is localized in the cytoplasm of breast cancer cells (Kumar et al., 2002) . The MTA1s is generated by alternative splicing at a cryptic splice site in exon 14, the deletion of 47 base-pair nucleotides, and a frame-shift involving the addition of novel 33 amino acids (Kumar et al., 2002) . MTA1s binds and inhibits the nuclear functions of ER-a by sequestering it to cytoplasm in breast cancer cells (Kumar et al., 2002) . However, ER-a sequestered in the cytoplasm remains functional and promotes the nongenomic action of ER-a in the cytoplasm such as MAPK stimulation. The expressions of MTA1 and MTA1s are not restricted to cancer cells as several normal mouse tissues and organs express substantial levels of these gene products (Toh et al., 1994; Mazumdar et al., 2001; Kumar et al., 2002) , suggesting a potential physiologic role of these proteins.
To better understand the cellular functions and targets of MTA1s in breast cancer cells, we performed a yeast two-hybrid screen to identify MTA1s-interacting proteins. One of several isolates was identified as a member of the casein kinase family, that is, casein kinase1-g2 (CKI-g2) as an interacting protein. The casein kinase I (CKI) family of serine/threonine kinases is ubiquitously expressed in a wide range of eukaryotes, including yeast and humans as well as in plants (Ullrich and Schlessinger, 1990; Gross and Anderson, 1998) . Although originally considered to be a protein Ser/Thr kinase (Zhai et al., 1995) , existing literature indicates the ability of several yeast CKI homologs to also undergo autophosphorylation on tyrosine residues, which is a characteristic of the so-called dual-specificity enzymes Cegielska et al., 1998; Rivers et al., 1998) . Although the yeast CKI isoforms have been well characterized, the functions of the mammalian CKI isoforms remain poorly understood (Dubois et al., 2001) . A conserved core kinase domain and variable amino-and carboxyl-terminal tails characterize the CKI family. In vertebrates, seven CKI isoforms have been isolated, including CKI-g1, 2 and 3. Recent studies suggest that rat CKI-g2 directly interacts with Nck adaptor protein (Lusier and Larose, 1997) . Rat CKI-g2 contains two juxtaposed proline-rich PXXP motifs, which are absent in CKI-g1 and CKI-g3. Human CKIg2 has 94% homology with the rat homolog. The CKIg2 has been localized on human chromosome 19p 13.3 (Kitabayashi et al., 1997) , and contains only one proline-rich motif. Currently known substrates of CKI include cytoskeletal proteins such as spectrin, troponin, myosin and tau (Simkowski and Tao, 1980) , and transcriptional components such as RNA polymerases I and II, SV40 T antigen and CREM (Dahmus, 1981; de Groot et al., 1993; Gra¨sser et al., 1988) . Flotow and Roach (1989) have shown rabbit muscle glycogen synthatase as a substrate for CKI. Recently, Marin et al. (2003) have shown that CKI phosphorylates Ser-45 of b-catenin priming the subsequent phosphorylation by glycogen synthatase 3 that in turn prevents its role in cell division. Mutations of the CKI target phosphorylation site in b-catenin have been correlated with thyroid tumors, adding up physiological significance to such observation (Garcia-Rostan et al., 1999 Marin et al., 2003) . The role of phosphorylation of p53 induced by CKI has also been verified by several groups (Knippschild et al., 1995; Dumaz et al., 1999) . Cooper and Lampe (2002) have also presented evidence identifying CKI playing a major role in the processing of Cx43, which is a member of the cannexin family of gap junction proteins. As the role of members of the CKI family becomes clearer, further identification of mammalian CKI substrates and CKI-binding proteins might help to clarify the putative functions of CKI.
Here we show that MTA1s interacts with CKI-g2 and that MTA1s is a substrate for CKI-g2. In addition, we demonstrate that CKI-g2 phosphorylation of MTA1s enhances its ability to sequester ER-a in the cytoplasm. Impairment of nuclear transactivation functions of ERa by MTA1s could be reversed by a mutant MTA1s deficient in possible casein kinase I phosphorylation site (serine residue at the 321 position). Furthermore, we found that estradiol stimulates the phosphorylation induced by CKI-g2. Together, these observations offer new insights about the potential regulation of MTA1s function by a ubiquitously expressed estrogen-responsive CKI-g2, and surfaces an additional nongenomic action of estrogen in breast cancer cells.
Results and discussion

Identification of CK I-g2 as MTA1s interacting protein
MTA1s is expressed in a wide range of tissues, yet the nature of its downstream targets remains unknown (Kumar et al., 2002) . To better understand the regulation of MTA1s, we wished to identify novel MTA1s-interacting proteins by a yeast two-hybrid screening of the human mammary gland cDNA expression library using the MTA1s full length (aa 1-429) as bait. Yeast cells expressing the Gal4 fusion protein were transformed with the MTA1s bait. Screening of 2 Â 10 6 transformants resulted in the isolation of several positive isolates. Sequencing of the positive clones identified several clones that encoded the partial cDNA of a previously characterized gene, CKI-g2 (GenBank Accession Number NM_001319). The identity of the isolated clone to that of CKI-g2 was confirmed by direct sequence analysis. To demonstrate the interaction between CKI-g2 and MTA1s, yeast cells were cotransfected with MTA1s or MTA1 (as a negative control) constructs with the CKI-g2 fragment isolated above. As shown in Figure 1a , the MTA1s-transformed colonies exhibited the ability to grow in medium lacking adenosine, histidine, tryptophan, and leucine (-AHLT) and also scored blue in a b-galactosidase assay, while cotransfection with the control GBK vector or MTA1 did not do so ( Figure 1a ).
Colocalization of CKI-g2 with MTA1s in breast cancer cells
We next explored the spatial relationship between CKIg2 and MTA1s in breast cancer cells using immunofluorescence and confocal scanning microscopy. We used antibodies against the tagged moieties for immunohistochemical studies. ZR-75 breast cancer cells stably expressing either T7-MTA1s or pcDNA (Kumar et al., 2002) were transfected with HA-CKI-g2, fixed in methanol and stained for HA-tag (green) and T7-tag (red), and counterstained for nuclear DNA (blue). As shown in Figure 1b , T7-MTA1s and HA-CKI-g2 were localized predominantly in the cytoplasm. Areas of colocalization of the T7-MTA1s and HA-CKI-g2 proteins resulted in the development of yellow fluorescence because of the merging of the red and green pixels ( Figure 1b) . Colocalization was also observed in ZR-75 cells transiently transfected with the HA-tagged CKI-g2 and Myc-tagged MTA1s (Figure 1c ).
CK I-g2 interacts with MTA1s in vitro and in vivo
To validate the interaction between CKI-g2 and MTA1s, we examined the ability of in vitro translated T7-MTA1s protein to bind with glutathione-S-transferase (GST)-CKI-g2 in GST pull-down assays. Results indicated that T7-MTA1s efficiently interacts with GST-CKI-g2 but not with GST alone (Figure 2a) . To demonstrate the noticed interaction of CKI-g2 and MTA1s in breast cancer cells, the ZR-75 cells were cotransfected with HA-tagged CKI-g2 or T7-tagged MTA1s or a pcDNA control vector. Cell lysates were immunoprecipitated with an anti-HA monoclonal antibody and sequentially immunoblotted with antibodies against T7 or HA. Results showed a specific interaction between the T7-MTA1s and HA-CKI-g2 in ZR-75 cells (Figure 2b ). Similarly specific interaction between T7-MTA1 and HA-CKI-g2 was also detected by coexpressing of HA-CKI-g2 in ZR-75 cells stably expressing T7-MTA1s but not in vector transfected ZR-75 cells (Figure 2c ).
MTA1s interacts with the C-terminal region of CK I-g2
Next we defined the minimal region of CKI-g2 required for its interaction with MTA1s. CKI-g2 has several important domains involved in protein-protein interactions, DNA binding, and signal transduction ( Figure 3a ). Several C-and N-terminal CKI-g2 deletion constructs were expressed as 
CK I-g2 inhibits transactivation functions of ER-a
Since CKI-g2 is an MTA1s-interacting protein and because MTA1s is known to sequester ER-a and inhibit Figure 2 Direct association of CKI-g2 with MTA1s. (a) CKI-g2 directly interacts with MTA1s. In vitro translated T7-MTA1s protein was incubated with GST-CKI-g2 or GST alone, and GST pull-down assays were performed (n ¼ 3). (b) ZR-75 cells were transiently transfected with T7-MTA1s and HA-CKI-g2 or a control vector. Immunoprecipitation was performed using anti-HA-Ab, and western blotting was carried out using antibodies against T7 and HA epitopes (n ¼ 3). (c) ZR-75 cells stably expressing T7-MTA1s were transiently transfected with HA-CKIg2. Immunoprecipitation was performed using anti-HA-Ab, and Western blotting was carried out using antibodies against T7 and HA epitopes. 
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SK Mishra et al its transactivation functions (Kumar et al., 2002) , we next investigated whether CKI-g2 has any modulating effect on the ER transactivation functions. To test this possibility, we examined the potential ability of CKI-g2 to influence the transcription from an ERE-luciferase reporter system. Expression of CKI-g2 inhibited both baseline as well as estradiol-stimulated ERE-driven transcription in the cells (Figure 4a ). As expected, coexpression of CKI-g2 along with MTA1s further potentiated (85% inhibition) the noticed inhibition of ER transactivation function as compared to the level of inhibition observed with CKI-g2 (60% inhibition) or with MTA1s (60% inhibition) alone (Figure 4a ). We also examined the effect of CKI-g2 on the ERE elements using a Gal4-ER/Gal4-luciferase assay system. This system involves transient transfection of two plasmids Gal4-AF2 (ligand-binding domain of ER-a and Gal4-luciferase reporter), and luciferase activation depends on E2 stimulation of the AF2 domain. In this assay the E2-mediated activation of the AF2 function was also inhibited by CKI-g2 (Figure 4b ). Similar to the EREluc reporter system, we observed that combined expression of CKI-g2 and MTA1s further repressed Gal4-luc activity (81% inhibition) as compared to expression of CKI-g2 (69% inhibition) or with MTA1s (57% inhibition) alone ( Figure 4b ). Next we examined the role of the kinase domain of CKI-g2 in the observed repression of ERE transactivation, and repeated the above studies with kinase-dead CKI-g2. Results indicated a lack of ERE repression by CKI-g2, suggesting a putative role of the kinase region of CKI-g2 in the noticed repression of ERE transactivation by CKI-g2 (Figure 4c ).
CK I-g2 phosphorylates MTA1s
Since CKI-g2 is a kinase enzyme, we investigated whether MTA1s is a substrate of CKI-g2. ZR-75 cells Gal4-AF2, Gal4-luciferase reporter and b-gal. One group was cotransfected with HA-CKI-g2 (1 mg/ well) whereas another set was cotransfected with Myc-MTA1s (1 mg/ well). In another group cells were cotransfected with both Myc-MTA1s and HA-CKI-g2. The whole transfection was also balanced with the corresponding vectors. Cells were stimulated with E2 (10 -9 M) for 16 h; the luciferase activity was then determined (n ¼ 3). (c) In another assay CKI-g2 wild type and kinase-dead CKI-g2 were used to see the effect on ERE-luciferase activity.
MTA1s interaction with CKI-c2 SK Mishra et al were transfected with HA-CKI-g2 or HA-pSVZeo control vector and cells were stimulated with estrogen before lysis. Cell lysates were immunoprecipitated with anti-HA monoclonal antibody to purify enzymatic active HA-CKI-g2 for in vitro kinase assay using GSTMTA1s as a substrate. As illustrated in Figure 5a , CKIg2 rapidly phosphorylated GST-MTA1s as compared to the level of MTA1s phosphorylation by control vector, suggesting that CKI-g2 phosphorylates MTA1s.
Next we examined the effect of CKI-g2 on MTA1s phosphorylation in vivo. ZR-75 cells stably expressing T7-MTA1s (Kumar et al., 2002) were transfected with HA-CKI-g2 or kinase-dead HA-CKI-g2 or HApZeoSV2 control vector, and metabolically labeled with 32 P-orthophosphoric acid followed by stimulation with estrogen, with or without pretreatment with a specific inhibitor for CKI (CKI-7) or antiestrogen ICI 182780. Cell lysates were immunoprecipitated with anti-T7-monoclonal antibody to analyse the status of T7-MTA1s. Results indicated that estrogen stimulates MTA1s phosphorylation, and pretreatment with CKI inhibitor or antiestrogen prevented the noticed estrogenmediated stimulation of CKI-g2 phosphorylation ( Figure 5b ). Next we examined whether MTA1s could be phosphorylated by the endogenous CKI-g2 in ZR-75 cells. Due to lack of suitable anti-MTA1s antibodies for immunoprecipitation assay, ZR-75 cells were transiently transfected with T7-MTA1s and labeled for 16 h with 32 P-orthophosphoric acid in the presence or absence of a specific inhibitor for CKI (CKI-7, Bioukar et al., 1999) , and MTA1s was immunoprecipiated with an anti-T7 mAb and analysed by a phosphoimager. Results from these experiments suggested that in spite of significant expression of T7-MTA1s in both the lanes, MTA1s was rapidly phosphorylated in ZR-75 cells and this was completely blocked by pretreatment with CKI inhibitor, suggesting that endogenous CKI-g2 phosphorylates MTA1s (Figure 5c ).
Since ER-a has been shown to be phosphorylated by CKII (Arnold et al., 1995; Tzeng and Klinge, 1996) , we next explored whether CKI-g2 could also phosphorylate ER-a. ZR-75 cells were transfected with HA-CKI-g2 or kinase-dead HA-CKI-g2, and cell lysates were verified for kinase activity on recombinant ER-a. There was no effect of HA-CKI-g2 on ER phosphorylation (Figure 5d ). The baseline ER phosphorylation could not be inhibited by CKI inhibitor (CKI-7). These results suggested that MTA1s is a v-interacting substrate and that the kinase function of CKI-g2 is required for MTA1s phosphorylation.
CK I-g2 promotes cytoplasmic ER-a sequestration and requirement of kinase activity for modulation of ER-a transactivation functions
Since CKI-g2 is an estrogen-responsive enzyme that phosphorylates MTA1s (this study), we next examined the impact of CKI-g2-induced phosphorylation of MTA1s on its ability to repress ER-a transactivation function. Analysis of MTA1s sequence revealed a probable site for phosphorylation by CKI-g2 (Cell Signaling Tech., 2002, database regarding substrate specificity of protein kinases determined by soluble peptide library, Kreegipuu et al., 1998) . In addition, analysis by ScanProsite and ExPASy programs (http:// us.expassy.org/cgi.bin/scan prosite) revealed that the NH 2 -terminus of MTA1s may be potentially phosphorylated by tyrosine kinases and protein kinase C, in addition to casein kinase. Accordingly, we mutated the P-orthophosphoric acid. Immunoprecipitation was performed with anti-T7-antibody. Cells were either treated with estrogen or ICI-182780 or CKI-g2 inhibitor (CKI-7). Signals were developed by using a phosphoimager. (c) ZR-75 cells transiently transfected with T7-MTA1s were metabolically labeled for 16 h with 32 P-orthophosphoric acid followed by treatment with or without CKI inhibitor (CKI-7). Immunoprecipitation was performed with anti-T7-antibody and phosphorylation of T7-MTA1s was analysed using a phosphoimager. (d) Kinase reaction was performed by using recombinant ER-a either in the absence or presence of estrogen. Besides, CKI-g2 inhibitor (CKI-7) and ICI -182780 compound were also used.
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SK Mishra et al serine residue at the 321 position (putative CKI-g2 phosphorylation site in MTA1s) to alanine (MTA1s-S321A) and examined its ability to be phosphorylated by CKI-g2. ZR-75 cells were transiently transfected with myc-CKI-g2 and T7-MTA1s or T7-MTA1s-S321A and labeled for 16 h with 32 P-orthophosphoric acid in the presence or absence of CKI-g2 inhibitor CKI-7, and T7-MTA1s was immunoprecipiated with an anti-T7 mAb and analysed by a phosphoimager ( Figure 6A) . Results indicated that myc-CKI-g2 rapidly phosphorylated T7-MTA1s, while the levels of phosphorylation of T7-MTA1s-S321A were significantly reduced as compared to T7-MTA1s (compare lane 3 with lane 2) and were comparable to T7-MTA1s treated with CKI inhibitor CKI-7 (compare lane 4 with lane 2) ( Figure 6A ).
We next tested the effect of the CKI-g2 site in MTA1s on its ability to repress ligand-induced ER-transactivation function. As shown in Figure 6B , substitution of serine to alanine in MTA1s resulted in a significant reduction in the ability of MTA1s to repress ER's transactivation function as compared to repression by the wild-type MTA1s. Furthermore, coexpression of CK1-g2 further suppressed MTA1s-mediated repression of ER transaction, while there was no significant potentiating effect of CK1-g2 on the ability of MTA1s-S321A We next wanted to verify the role of CKI-g2 in ER-a sequestration by MTA1s. Using confocal scanning microscopy, we observed that coexpression of HAtagged CKI-g2 and Myc-MTA1s promoted the levels of ER-a in the cytoplasm with a concurrent decrease in the nucleus, as compared to cells not expressing HA-CKIg2. A cell negative for CKI-g2 retains ER-a in the nucleus (cell shown in the upper part of the panel). Together these observations suggested a role of CKI-g2, an MTA1s-binding protein, in supporting the ER-a sequestration function of MTA1s.
We further investigated whether coexpression of CKIg2 influences the ability of MTA1s to sequester ER-a in the cytoplasm. To test this possibility, we examined the effect of HA-CKI-g2 and T7-MTA1s either alone or in combination with the subcellular localization of ER in ZR-75 cells by confocal scanning microscopy. As illustrated in Figure 6D , coexpression of CKI-g2 and MTA1s was accompanied by an enhanced localization of ER-a in the cytoplasm whereas cells negative for MTA1s transfection or pcDNA (control vector) transfected cells do not show such an effect. However, when mutated MTA1s (S321A) was transfected, such sequestration could not be detected. It raises the possibility that the kinase function of CKI-g2 might be important in the noticed potentiating corepressing effect of CKI-g2.
In summary, the results presented here demonstrate that CKI-g2 is an MTA1s-interacting protein that phosphorylates and potentiates the ability of MTA1s to sequester ER and inhibit its transactivation functions. These extranuclear effects of estrogen might have important implications in regulating the action of MTA1s in human cells. In addition, it is also possible that estrogen regulation of CKI-g2 might serve as a negative regulator of ER-a nuclear functions by enabling MTA1s to sequester ER-a to cytoplasm. Clearly, additional studies are needed to address these emerging new issues.
Materials and methods
Plasmid construction and two-hybrid library screening
The full-length MTA1s was subcloned into pGBKT7-MTA1 construct by removing KpnI and SacII fragment (internal MTA1 site) and ligating with KpnI and SacII fragment from MTA1-pcDNA construct that expresses proteins fused to the GAL4-DNA binding domain (DNA-BD) (Clontech). MTA1 baits were constructed by deleting 1-254 amino acids from the N-terminal of MTA1 by cutting and self-ligating with Nco1 that cleaves the first 254 amino acids. The remaining 255-715 amino acids of the C-terminal MTA1 were used as the bait. These baits were used to screen a mammary gland cDNA library fused to the Gal4 activation domain (Clontech) (Mishra et al., 2003) . Screening was performed according to the manufacturer's instructions. Positive clones were also verified by one-on-one transformations and selection on agar plates lacking leucine, and tryptophan (ÀLT) or adenine, histidine, leucine, and tryptophan (ÀAHLT) and also processed for b-galactosidase (b-gal) assay (Mishra et al., 2003) .
MTA1s and CKI-g2 construct
MTA1s cDNA and constructs were made as described earlier . For CKI-g2 a partial cDNA encompassing the C-terminal region of CKI-g2 (bps 577-1248) was originally pulled out from a mouse T-cell library in a yeast two-hybrid screen using the three SH3 domains of Nck as a bait (Lusier and Larose, 1997) . The mouse full-length CKI-g2 cDNA was assembled from overlapping clones isolated from the hybridization of a mouse brain cDNA library (Stratagene) using, as a probe, the partial CKI-g2 C-terminal cDNA previously described. By overlapping PCR, a kinase-deficient CKI-g2 was generated by introducing a point mutation (K 75 R) in the ATP binding site of the kinase domain. A cDNA encoding the kinase domain of CKI-g (bps 1-1020) but lacking its C-terminal extension was generated by PCR using appropriate oligonucleotides. Using appropriate oligonucleotides, we amplified CKI-g2 cDNA encoding CKI-g2 protein deleted of its first 280 (280-415) or last 7 (DKCC) residues. Most of the cDNAs were subcloned downstream of a Kozak sequence and in frame with a HA epitope sequence into the mammalian expression vector pZeoSV2 (Invitrogen), except the C-terminal CKI-g2 cDNA, which was subcloned into the vector pcDNA 3.1 (Invitrogen). All constructs were fully sequenced to confirm their identity and to ensure that no unwanted mutation had been introduced during their creation.
Cell culture, transfection, and antibodies MCF-7, ZR-75/pcDNA, and ZR-75/MTA1s breast cancer cells were maintained in DMEM/F12 (1 : 1) supplemented with 10% FBS. For reporter gene and plasmid transfection assays, cells were cultured in phenol red-free medium containing 5% charcoal-stripped serum for 48 h and then transfected with plasmid using Fugene-6 reagents (Roche, USA). The cells were lysed with passive lysis buffer (Promega, USA) and luciferase activity was measured. The activity of b-galactosidase reporter was used to correct the transfection efficiencies (Mazumdar et al., 2001) . Cell lysates were analysed in 10% SDSpolyacrylamide gel, transfered and probed with respective antibody. HA-tagged mouse monoclonal from Boeringer Manheim, T7 tagged, and T7-tagged biotinylated mouse monoclonal antibody were from Novagen.
In vitro transcription and translation
In vitro transcription and translation of a desired protein was performed using the Transcription and Translation System (Promega). In all, 1 mg of the test plasmid was in vitro translated in the presence of 35 S-methionine in a total reaction volume of 50 ml. The reaction was diluted to 1 ml with NP-40 lysis buffer and an aliquot (250 ml) was used for each pull-down assay. The efficiency of translation reaction was verified by running an aliquot from the reaction by SDS-PAGE and autoradiography.
Gst pull-down assay and in vitro kinase assay and immunoprecipitations
For the GST pull-down assays, equal amounts of GST, GSTMTA1s, GST-CKI proteins immobilized to glutathione Sepharose bead (Amarsham) were incubated with in vitrotranslated 35 S-labeled protein. The mixture was incubated for 4 h at 41C, washed with NP40 lysis buffer, bound proteins were eluted with 2 Â SDS buffer, separated on SDS-PAGE, and developed for analysis. For in vitro kinase reaction, cell lysates were immunoprecipitated with anti-GST or HA antibodies to detect GST-MTA1s or HA-CKI-g2, respectively. Kinase assays were performed in 40 ml of kinase reaction buffer (20 mM HEPES pH 7.2; 10 mM MgCl 2 ; 10 mM MnCl 2 ; 1 mM DTT; containing 10 mCi [ 32 P]-ATP and 25 mM of cold ATP for 30 min at 301C). For immunoprecipitation-based assays, cells were lysed in NP40 lysis buffer (50 mM Tris-HCl pH7.5; 50 mM NaCl; 0.5% NP40; 100 mM NaF; 2 mM NaVO 5 ; 1 mM PMSF; 10 mg/ml leupeptine; 10 mg/ml apoptinin), and assays were performed by rotating antibodies at 41C for 4 h. For the ER-a phosphorylation study, recombinant ER-a protein was procured from affinity BioReagent.
Metabolic labeling
Breast cancer cells were grown to 30% confluency and were shifted to phenol red-free medium containing 3% DCC serum.
Cells were transfected with desired plasmid for 24 h and subsequently labeled with 32 P-orthophosphoric acid for 16 h in phosphate-free medium, and were treated either with estrogen, ICI or CKI inhibitor (CKI-7) (Seikagaku Corp.). Cells were lysed on ice and clarified lysate was subjected to immunoprecipitation assay. Precipitated materials were then resolved in 10% SDS-PAGE and analysed.
Abbreviations ER, estrogen receptor-alpha; ERE, estrogen response element; NR, nuclear receptor; MTA1s, metastasis-associated protein-1 short form; E2, 17-b-estrodiol; AF domain, activation function domain; luc, luciferase.
